^
Association details:
| Biomarker: | SOX10 underexpression |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Excerpt:
In a heterogeneous population of melanoma cells having varying levels of SOX10 suppression, cells with low SOX10 and consequently high EGFR expression are rapidly enriched in the presence of drug, but this is reversed when the drug treatment is discontinued. We find evidence for SOX10 loss and/or activation of TGF-β signalling in 4 of the 6 EGFR-positive drug-resistant melanoma patient samples.
DOI:
10.1038/nature13121
Source:
Title:
40 - Targeting SOX10-deficient cells to reduce resistance to targeted therapy in melanoma
Published date:
03/10/2021
Excerpt:
...melanoma models...cell lines generated from xenograft tumors that have acquired resistance to either vemurafenib, paradox-breaking BRAFi or the combination of BRAFi + MEKi showed dramatically reduced SOX10 expression compared to their parental counterparts.
